Johannes Fexer1, Ewan Donnachie, Antonius Schneider, Stefan Wagenpfeil, Manfred Keller, Frank Hofmann, Michael Mehring. 1. Institute of General Practice, Klinikum rechts der Isar der TU M¨nchen, National Association of Statutory Health Insurance Physicians of Bavaria, Munich, Institute of Medical Biometrics, Epidemiology, and Medical Informatics (IMBEI) of the Saarland University, Homburg/Saar, F. Fexer and E. Donnachie share primary authorship of this article.
Abstract
BACKGROUND: Theophylline is often used to treat chronic obstructive pulmonary disease (COPD). Current evidence leaves the effectiveness and safety of this drug open to question. Thus, we evaluated the effectiveness of theophylline on the rate of hospitalizations and disease exacerbations by examining routine data from the ambulatory disease management program for COPD in the German state of Bavaria. METHOD: Data sets from a total of 30 330 patients were examined. Logistic regression models were used to calculate propensity scores that controlled for baseline characteristics. These propensity scores, in turn, were used to create comparable patient groups, which were observed for a median follow-up time of 9 quarters (the theophylline group) and 10 quarters (the control group). RESULTS: 1496 patients with first prescription of theophylline were matched with 1496 patients with no record of theophylline treatment. 1. The probability of suffering an exacerbation during the period of observation, was 33.5% for the control group and 43.4% for the theophylline group [hazard ratio (HR) 1.41; 95% confidence interval (CI) 1.24 to 1.60], yielding a number needed to harm (NNH) of 11 (95% CI 7.7 to 20.9). The probability for hospitalization was 11.4% for the control group and 17.4% of the theophylline group (HR 1.61; 95% CI 1.29 to 2.01), yielding a NNH of 17 (95%CI 11.0-34.5). CONCLUSION: Treatment with theophylline is associated with an elevated incidence of exacerbations and hospitalizations. The therapeutic value of this drug should be reconsidered and investigated in further studies.
BACKGROUND:Theophylline is often used to treat chronic obstructive pulmonary disease (COPD). Current evidence leaves the effectiveness and safety of this drug open to question. Thus, we evaluated the effectiveness of theophylline on the rate of hospitalizations and disease exacerbations by examining routine data from the ambulatory disease management program for COPD in the German state of Bavaria. METHOD: Data sets from a total of 30 330 patients were examined. Logistic regression models were used to calculate propensity scores that controlled for baseline characteristics. These propensity scores, in turn, were used to create comparable patient groups, which were observed for a median follow-up time of 9 quarters (the theophylline group) and 10 quarters (the control group). RESULTS: 1496 patients with first prescription of theophylline were matched with 1496 patients with no record of theophylline treatment. 1. The probability of suffering an exacerbation during the period of observation, was 33.5% for the control group and 43.4% for the theophylline group [hazard ratio (HR) 1.41; 95% confidence interval (CI) 1.24 to 1.60], yielding a number needed to harm (NNH) of 11 (95% CI 7.7 to 20.9). The probability for hospitalization was 11.4% for the control group and 17.4% of the theophylline group (HR 1.61; 95% CI 1.29 to 2.01), yielding a NNH of 17 (95%CI 11.0-34.5). CONCLUSION: Treatment with theophylline is associated with an elevated incidence of exacerbations and hospitalizations. The therapeutic value of this drug should be reconsidered and investigated in further studies.
Authors: Andrea Rossi; Peter Kristufek; Bernard E Levine; Moira H Thomson; Denise Till; John Kottakis; Giovanni Della Cioppa Journal: Chest Date: 2002-04 Impact factor: 9.410
Authors: A Sonia Buist; Mary Ann McBurnie; William M Vollmer; Suzanne Gillespie; Peter Burney; David M Mannino; Ana M B Menezes; Sean D Sullivan; Todd A Lee; Kevin B Weiss; Robert L Jensen; Guy B Marks; Amund Gulsvik; Ewa Nizankowska-Mogilnicka Journal: Lancet Date: 2007-09-01 Impact factor: 79.321
Authors: Michael Mehring; Antonius Schneider; Johannes Fexer; Ewan Donnachie; Manfred Keller; Frank Hofmann; Stefan Wagenpfeil Journal: Dtsch Arztebl Int Date: 2014-09-19 Impact factor: 5.594
Authors: Jana Graf; Rudolf A Jörres; Tanja Lucke; Dennis Nowak; Claus F Vogelmeier; Joachim H Ficker Journal: Dtsch Arztebl Int Date: 2018-09-14 Impact factor: 5.594